Langer lab spin­out Lyn­dra rais­es $60.5M in bid to re­place ex­ist­ing HIV, schiz­o­phre­nia, opi­oid abuse treat­ments

Two months af­ter un­veil­ing Phase II da­ta for their long-act­ing schiz­o­phre­nia pill, Lyn­dra Ther­a­peu­tics has raised a $60.5 mil­lion Se­ries C to push it through …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER